Leerink Partners Initiates Tekmira Pharmaceuticals At Outperform

Analysts at Leerink Partners initiated coverage on Tekmira Pharmaceuticals

with a Outperform rating. The target price for Tekmira Pharmaceuticals is set to $25. Tekmira Pharmaceuticals' shares gained 6.08% to $19.18 in pre-market trading.